Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
Want to see QNRX full AI Analyst Report?
QNRX Stock Chart & Stats
$11.72
-$0.04(-5.59%)
At close: 4:00 PM EST
$11.72
-$0.04(-5.59%)
Day’s Range― - ―
52-Week Range$4.10 - $41.80
Previous CloseN/A
Volume155.80K
Average Volume (3M)629.04K
Market Cap
$9.22M
Enterprise Value-$148.40K
Total Cash (Recent Filing)$3.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.94
Next Earnings
Aug 06, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.68
Shares Outstanding2,008,418
10 Day Avg. Volume1,633,105
30 Day Avg. Volume629,040
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-1.60
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.95
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$35.00Price Target Upside198.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.18
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetAbsence of debt reduces fixed financial obligations and lowers bankruptcy risk, giving management flexibility to prioritize R&D or partnerships. Over 2–6 months this supports funding negotiations and licensing talks and improves negotiating leverage with potential collaborators.
Regulatory Designations & ExclusivityMultiple official designations create durable development advantages: prioritized consultations, reduced fees, potential priority review and market exclusivity (e.g., up to 10 years in Japan). These structural incentives improve economics and strategic options for partnering or commercialization.
Clear Clinical Development PathwayA defined timeline with ongoing Phase 2 trials and a planned pivotal Phase 3 toward a potential 2027 NDA provides concrete de-risking milestones. This roadmap enables milestone-driven financing, partnering timelines and operational planning over the next 6–12 months.
Bears Say
Pre-commercial With No RevenueThe company remains pre-revenue with sustained operating and net losses, meaning ongoing operations rely entirely on external funding. Over several months this structural absence of product revenue raises execution risk and forces dependence on capital markets or partners to continue development.
High Cash BurnMaterial negative operating and free cash flow indicate significant cash consumption tied to clinical programs. Persistently high burn shortens runway, elevates the probability of near-term financing or partnerships, and can constrain strategic choices or delay commercialization plans.
Eroding Equity And Modest AssetsDeclining shareholder equity and relatively small total assets reduce the firm's financial flexibility to self-fund pivotal trials or early commercialization. This structural weakness increases reliance on external capital and may force dilutive financings or disadvantageous partnerships in coming months.
Quoin Pharmaceuticals News
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $4.10 and its highest was $41.80 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Quoin Pharmaceuticals’s market cap is $9.22M.
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 54 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on May 07, 2026. The company reported -$1.77 earnings per share for the quarter, beating the consensus estimate of -$2.17 by $0.4.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -1.61.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 2,008,418 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$1.77 in its last earnings report, beating expectations of -$2.17. Following the earnings report the stock price went down -0.933%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
QNRX Stock 12 Month Forecast
Average Price Target
$35.00
▲(198.63% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Jaguar Animal Health
―
Adial Pharmaceuticals
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
73.24% Insiders
20.72% Other Institutional Investors
6.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---